1392307-77-5

Upstream product

• 1392307-50-4 (2R,3R,4R)-2-(benzyloxy)-3-(tert-butyldimethylsilyloxy)-4,8-dimethylnon-7-en-1-ol 
• 1392307-51-5 (4R,5R,6R,(E))-ethyl 4-(benzyloxy)-5-(tert-butyldimethylsilyloxy)-6,10-dimethylundeca-2,9-dienoate 
• 160488-95-9 (2S,3R)-3,7-dimethyl-6-octene-1,2-diol 
• 1392307-52-6 (4R,5R,6R,(E))-4-(benzyloxy)-5-(tert-butyldimethylsilyloxy)-6,10-dimethylundeca-2,9-dien-1-ol 
• 1392307-53-7 ((4R,5R,6R,(E))-4-(benzyloxy)-1-bromo-6,10-dimethylundeca-2,9-dien-5-yloxy)(tert-butyl)dimethylsilane 
• 106-72-9 (R)-(-)-2,6-dimethyl-5-heptenal 
• 1392307-55-9 (2R,3R,4R,5R)-3-(benzyloxy)-4-(tert-butyldimethylsilyloxy)-5-methyl-2-vinylcyclohexanecarbaldehyde 
• 1392307-76-4 (1S,2R,3R,4R,5R)-methyl 3-(benzyloxy)-4-(tert-butyldimethylsilyloxy)-5-methyl-2-vinylcyclohexanecarboxylate 
• 1449483-39-9 C₂₈H₄₆O₄Si 
• 1449483-40-2 (4R,5R,6R,E)-4-(benzyloxy)-5-(tert-butyldimethylsilyloxy)-6-methyl-9-oxonon-2-enylacetate 

Relevant academic research and scientific papers

Total synthesis and biological evaluation of (-)-atrop-abyssomicin C

Enantioselective synthesis of a marine antibiotic (-)-atrop-abyssomicin C was accomplished in 21 steps, in 1.8% overall yield (4%, based on the recovered starting material). The key steps of the synthesis are the formation of the functionalized cyclohexane core by an organocatalyzed Tsuji-Trost reaction, the formation of a tricyclic spirotetronate unit by a gold-catalyzed reaction sequence and the highly efficient eleven-membered ring closure by a Nozaki-Hiyama-Kishi reaction. Biological tests showed all abyssomicin derivatives to possess strong antibacterial activity against methicillin resistant S. aureus strains; however, they also proved to be cytotoxic, both to malignant and to normal somatic cells. The Royal Society of Chemistry.